3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
4
Nivolumab
3
Itraconazole
2
tucatinib
1
tremelimumab
1
regorafenib
1
pertuzumab
1
lenvatinib
1
larotrectinib
1
durvalumab
1
cemiplimab
1
brigimadlin
1
aflibercept
1
Trastuzumab
1
Ritonavir
1
Paclitaxel
1
Fulvestrant
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Capecitabine
1
Antibodies
1
AZD9833
1
AZD5305
1
AZD 6244
1
ARX788
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
brigimadlin
×
Breast
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn